Compare Mondaycom Ltd (MNDY) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mondaycom Ltd vs Summit Therapeutics Inc — how do they compare? Mondaycom Ltd trades at $88.96 (market cap $3.76B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 3.6× Mondaycom Ltd's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mondaycom Ltd for 16 Days and Summit Therapeutics Inc for 16 Days on average.
| MNDY | SMMT | |
|---|---|---|
Market Cap | $3.76B | $13.71B |
Volume | 836,200 | 6,173,057 |
Sector | Technology | Health |
52-Week High | $205.24 | $26.38 |
52-Week Low | $58.81 | $12.43 |
Typical Hold Time | 16 Days | 16 Days |
Enterprise Value | $2.92B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monday.com (MNDY) trades at $88.91, up 6.47% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with revenue growth to $1.23B in 2025, net income of $118.74M, and consistent earnings beats. Recent news highlights AI integration at Elevate '26 conference and inclusion in growth stock lists. Analyst consensus remains strongly bullish with 17 buy ratings and $108.64 price target.
Outlook remains positive given strong enterprise client growth and AI adoption, though elevated valuation ratios (P/E 37.69) and competitive pressures from Meta's enterprise push present risks. The stock offers growth potential but requires monitoring of profit margin sustainability and market volatility.
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
